Why the Clinuvel Pharmaceuticals share price is up 111% in 2018

One of the best performers on the local market this year has been the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price.

Since the start of the year the biopharmaceutical company’s shares have risen a staggering 111%.

And that is despite its shares pulling back by over 30% since peaking at $24.10 in September.

Why has the Clinuvel Pharmaceuticals share price doubled in value this year?

For those that are not familiar with the company, Clinuvel is a global biopharmaceutical company which is focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.

Investors have been buying the company’s shares this year due largely to the potential of its SCENESSE product.

SCENESSE has been developed as a first-line pharmaceutical product aimed at treating patients with the rare genetic disorder erythropoietic protoporphyria (EPP).

What is EPP?

The company explains that “EPP is a rare life-long genetic disease found mainly in fair-skinned people. It is characterised by severe phototoxicity (intolerance of light) of the skin resulting in intolerable pain, swelling and scarring, usually of exposed areas such as the face, hands and feet. Reactions can vary from mild to extreme with hospitalisation and powerful pain killers required in the worst cases.”

Although the company estimates that just 4,000 people are affected by EPP in the U.S. and 10,000 globally, the product has the potential to generate meaningful revenues.

In fact, the product is available for sale in Europe at present and underpinned the company’s latest jump in quarterly cash receipts.

Cash receipts rose 89% to $10.75 million in the September quarter.

And with its FDA filing now complete, it may not be long until the product is made available to U.S. sufferers. This would potentially give its cash receipts another sizeable boost.

Should you invest?

I like Clinuvel Pharmaceuticals and think it could be a good long term investment, however it is a reasonably high risk one.

So if you have a lower tolerance for risk you might be better off looking at the likes of CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX) instead.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!